Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna's (MRNA) COVID-19 vaccine sales beat expectations. The company delivers 297 million doses of its COVID-19 vaccine during the fourth quarter.

Moderna (MRNA) Q4 Earnings Top, COVID-19 Vaccine Brings $7B

Moderna Chief Medical Officer Paul Burton said Covid is entering an endemic phase in the northern hemisphere.

Moderna says Covid is entering an endemic phase, but annual vaccines will be needed

Moderna Inc. (NASDAQ: MRNA) shares are trading after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback. Moderna reported quarterly earnings of $11.29 per share, beating the analyst consensus estimate of $9.90.

Moderna Rallies After Earnings Print: Could A Technical Reversal Be In Sight?

The biotech's latest earnings report is giving investors a reason to cheer today.

Why Moderna Stock Is Surging Higher Today

Adobe

U.S. indices finished higher as stocks sharply rebounded after falling following the Russian invasion of Ukraine. The Nasdaq composite finished higher by 3.34% to 13,473; The Invesco QQQ Trust Series 1 (NASDAQ: QQQ) gained 3.36% to $340.49 The S&P 500 traded higher by 1.50% to 4,288; The.

Nasdaq Stages Epic Intraday Recovery After Russia Invades Ukraine; Adobe, Moderna Lead Boost

Moderna (MRNA) delivered earnings and revenue surprises of 14.85% and 7.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Beats Q4 Earnings and Revenue Estimates

Announcement follows CHMP's previous decision to adopt a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include adolescents 12 years of age and older. CAMBRIDGE, MA / ACCESSWIRE / February 24, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the conditional marketing authorization (CMA) to include a 50 µg two-dose series of Spikevax, the Company's vaccine against COVID-19, in children ages 6-11 years.

EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union

Moderna Inc bucked the slump in global markets after the vaccine maker last night upped its forecast for sales of its Covid jab. The US pharma now expects to generate sales of US$19bn from its mRNA vaccine, compared to US$18.5bn previously with US$3bn worth of additional doses under option for booster campaigns.

Moderna bucks market slump as it ups forecast for Covid-19 jab revenues

The biotech also announced a $3 billion share repurchase plan.

Moderna Beats Earnings Estimates. The Stock Is Up.

Moderna CEO Stephane Bancel told FOX Business' "Mornings with Maria" that it's "a bit early" to tell whether a Russian invasion will impact the company.

Moderna CEO on Russia invading Ukraine, new COVID variant

Moderna also announced a $3 billion share repurchase plan

Moderna Beats Earnings Estimates. The Stock Is Down.

Moderna Inc. MRNA, -6.37% beat earnings and revenue expectations for the fourth quarter of 2021 after announcing Thursday that its COVID-19 vaccine brought in nearly $7 billion in product sales during the final three months of the year. Moderna had a profit of $4.8 billion, or $11.29 per share, in the fourth quarter of 2021, after reporting a loss of $272 million, or 69 cents per share, in the fourth quarter of 2020.

Moderna's COVID-19 shot generated $6.9 billion in sales in the fourth quarter

Moderna Inc on Thursday raised its full-year sales forecast for its COVID-19 vaccine by 2.7% to $19 billion, as it seeks to ramp up manufacturing following production problems last year.

Moderna raises 2022 COVID vaccine sales forecast to $19 billion

Moderna beat on its top and bottom lines, reporting earnings per share of $11.29 and revenue of $7.2 billion.

Moderna expects at least $19 billion in Covid vaccine sales in 2022, reports big fourth-quarter earnings beat

Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29 Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29 Moderna increased its 2022 signed advance purchase agreements to approximately $19 billion, with additional signed options of approximately $3 billion; numerous discussions ongoing with governments for the fall of 2022 and 2023 Moderna received full U.S. FDA approval for COVID-19 vaccine, Spikevax Moderna announces new bivalent booster candidate (mRNA-1273.214) combining Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273) Company now has 44 programs in development Moderna announces a new $3 billion share repurchase plan CAMBRIDGE, MA / ACCESSWIRE / February 24, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter of fiscal year 2021. "Spikevax is now approved in more than 70 countries around the world protecting hundreds of millions of people and real-world evidence from multiple independent studies has confirmed its strong effectiveness," said Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates

AstraZeneca

Novavax

Pfizer

Here are four pharma stocks that looks attractive for the long-term. Deep product development pipelines will ensure steady revenue and cash flow growth.

4 Pharma Stocks to Buy Even if the Pandemic Ends

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 9.7% at $149.11 after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback. Moderna reported quarterly earnings of $11.29 per share which beat the analyst.

What's Going On With Moderna Shares Today?

Moderna Inc (NASDAQ: MRNA) reports a Q4 EPS of $11.29, a turnaround from an EPS loss of $(0.69) a year ago, beating the consensus estimate of $9.90. The Company clocked Q4 revenues of $7.21 billion compared to just $571 million a year ago, beating the consensus of $6.79 billion.

Moderna Beats On Q4 Earnings, Announces $3B Buyback; Expects ~$19B In FY22 COVID-19 Vax Sales

Moderna stock fell 6% despite the bullish projection, pushing shares down nearly 72% below their August all-time high.

Moderna Stock Crash Worsens Even After Morgan Stanley Says Flu Vaccine Results Could Boost Shares

Medtronic

Regeneron Pharmaceuticals

Teladoc

Can these top health care stocks be the way to go amidst all the uncertainty in the stock market now?

Best Stocks To Invest In Right Now? 5 Health Care Stocks In Focus

A new COVID-19 vaccine option could be on its way to the market.

Why Moderna Stock Is Falling Today

The shares of Moderna Inc (NASDAQ:MRNA) are down 4.7% at $138.18 this afternoon, as investors gear up for the vaccine company's fourth-quarter earnings report, due out before the open tomorrow, Feb.  24.

Options Bears Target Moderna Stock Ahead of Earnings Report

Aerie Pharmaceuticals

Emergent BioSolutions

Editas Medicine

Vir Biotechnology

Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.

Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More

Booking Hlds

Lemonade

Planet Fitness

Skillz

Will these 5 companies break out, or break down, after they report earnings this week?

5 Intriguing Earnings Charts

The CDC said males ages 12- to 39-years-old should consider waiting 8 weeks between the first and second doses of Pfizer and Moderna's vaccines.

News for Moderna Stock (MRNA)